Conference Coverage

SSRI tied to improved cognition in comorbid depression, dementia


 

FROM CTAD 2022

Small trial, open-label design

In a comment, Claire Sexton, DPhil, senior director of scientific programs and outreach at the Alzheimer’s Association, said the study “reflects a valuable aspect of treatment research because of the close connection between depression and dementia. Depression is a known risk factor for dementia, including Alzheimer’s disease, and those who have dementia may experience depression.”

senior director of scientific programs and outreach at the Alzheimer’s Association Alzheimer’s Association

Dr. Claire Sexton

She cautioned, however, that the trial was small and had an open-label design instead of the “gold standard” of a double-blinded trial with a control group.

The study was funded by Lundbeck, where Dr. Christensen is an employee. Another author is a Lundbeck employee, and a third author reported various disclosures. Dr. Sexton reported no disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Poor visual acuity linked to depression, changes in brain structure
Federal Practitioner
‘Disturbing’ lack of follow-up care after psychiatric crises
Federal Practitioner
Self-worth training boosts ketamine’s effects in severe depression
Federal Practitioner
Preexisting mental illness symptoms spiked during pandemic
Federal Practitioner
Brussels terror attack victim euthanized in Belgium at age 23
Federal Practitioner
Hormone therapy–depression link may depend on mode of administration
Federal Practitioner
Major depression treatments boost brain connectivity
Federal Practitioner
Single dose of psilocybin for major depression tied to short-term remission
Federal Practitioner
The danger when doctors don’t get mental health help
Federal Practitioner
Medicaid Expansion and Veterans’ Reliance on the VA for Depression Care
Federal Practitioner